In pancreatic cancer, L-type amino acid transporter 2 (LAT2) promoted glycolysis and reduced gemcitabine sensitivity by regulating glutamine-dependent mTOR [79]. This evidence concerns the gene LAT2 and familial pancreatic carcinoma.